FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Tyr	e Responses)																	
1. Name and Address of Reporting Person * Mendelsohn Aaron				2. Issuer Name and Ticker or Trading Symbol Vivani Medical, Inc. [VANI]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last) (First) (Middle) C/O 5858 HORTON ST, SUITE 280				3. Date of Earliest Transaction (Month/Day/Year) 08/30/2022								Officer (give t	title below)		er (specify bel	ow)			
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person								
	VILLE, CA		(7:)														.,		
(City	")	(State)	(Zip)				Table	I - N	on-De	erivative	e Se	curities	Acqui	ired, D	Disposed o	of, or Benef	icially Owne	d	
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		(Instr. 8)		tion	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Form:	7. Nature of Indirect Beneficial Ownership		
			Co			de	V	Amour	ınt	(A) or (D)	Price	(Ilisu. 3 aliu 4)			or Indirect (I) (Instr. 4)	(Instr. 4)			
Common Stock 08/			08/30/2022				J	I)		178,1	70	A	\$ 0	178,170			D		
Common Stock 0			08/30/2022			JÜ	I)		150,93	30	A	\$ 0	150,930			I	Trusts (2)		
Common Stock		08/30/2022)22		J <u>(1)</u>			747,38	87	A	\$ 0	747,387			I	See Footnote (3)			
Reminder: I	Report on a se	eparate line for each	class of securities be	- Deriva	tive S	ecuriti	es Acq	i i i i	Perso in this a curr d, Dis	ons who s form rently v	are valid	not red d OMB	quired contr	d to re	spond u nber.		on containe form displa		1474 (9-02)
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	e Execution Date, if		4. 5. Num f Transaction of Deri Code Securit		mber fivative ties red (A) posed 3, 4,		options, convertible securiti Date Exercisable and xpiration Date Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Owner Form of Deriva Securit Direct or Indi	Ownersh y: (Instr. 4)			
				Code	V	(A)	(D)	Date Exer	e rcisabl		ate	tion	Title		Amount or Number of Shares		(Instr. 4)	(Instr.	1)
Common Stock Option	\$ 3.15	08/30/2022		J(4)	í	30,18	7	08/	30/20)22 11	1/13	3/2028		mon ock	30,187	\$ 0	30,187	D	
Common Stock Option	\$ 3.15	08/30/2022		J(4)		30,18	7	08/	30/20)22 11	1/11	/2029		nmon	30,187	\$ 0	30,187	D	

Common

Stock

Common

Stock

08/30/2022 11/19/2030

08/30/2022 12/14/2023

\$ 0

\$0

30,187

25,927

D

I

See

<u>(6)</u>

Footnote

30,187

25,927

Reporting Owners

\$ 3.15

\$ 3.15

Common

Stock

Option

Warrants

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Mendelsohn Aaron C/O 5858 HORTON ST, SUITE 280 EMERYVILLE, CA 94608	X						

08/30/2022

08/30/2022

<u>J(4)</u>

<u>J(5)</u>

30,187

25,927

Signatures

/s/ Aaron Mendelsohn	08/31/2022			
**Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents shares of common stock issued in the acquisition transaction of Nano Precision Medical Inc. consummated August 30, 2022.
- (2) Represents five trusts, each one established for a separate grandchild of the Reporting Person, each trust owning an aggregate of 30,186 shares of common stock, all trusts with the same terms, over which the Reporting Person has voting and dispositive authority.
- Represents shares of common stock owned by MFE, LLC over which the Reporting Person has voting and dispositive authority. The Reporting Person disclaims pecuniary interest in 20% of (3) the limited liability company and therefore 149,478 shares of common stock held by the limited liability company, which are beneficially owned by other members of the limited liability company
- (4) Represents the replacement option to be issued by Vivian Medical, Inc. (f/k/a Second Sight Medical Products, Inc.) at the effective time of the merger acquisition thereof, pursuant to the terms of the Agreement and Plan of Merger entered into on February 4, 2022.
- (5) Represents warrants to purchase shares of common stock assumed on the effective date of the acquisition of Nano Precision medical, Inc., consummated on August 30, 2022, pursuant to the Agreement and Plan of Merger dated February 4, 2022.
- Represents shares of common stock underlying a warrant owned by MFE, LLC over which the Reporting Person has voting and dispositive authority. The Reporting Person disclaims (6) pecuniary interest in 20% of the limited liability company and therefore 5,185 shares of common stock held by the limited liability company, which are beneficially owned by other members of the limited liability company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.